Medicis expects FDA approval of Perlane, undisclosed drug in Q4

By Jennifer Lanning Drey

Eugene, Ore., Sept. 8 - Medicis Pharmaceutical Corp. expects to receive Food and Drug Administration approval in the fourth quarter for Perlane, its injectable, non-animal stabilized hyaluronic acid gel for treatment of fine lines, said Mark Prygocki, Medicis chief financial officer, at the Thomas Weisel health care conference Friday.

Medicis also hopes to gain FDA approval for another drug in the fourth quarter; however, the company has not yet provided any details about the potential product, Prygocki said.

"We haven't described it, but it really fills out the handful of products that will bring us into 2007, Prygocki said.

In addition, Medicis plans to concentrate its forthcoming efforts on increasing sales of Restylane, Vanos and Solodyn, which are its currently approved products that generate the highest revenues, he said.

The company will put less emphasis in 2007 on other approved products including Loprox, Triax and Plexion, Prygocki added.

Medicis will continue development of Reloxin in 2007, he said.

Reloxin is a botulinum toxin that the company will develop, distribute and commercialize in certain areas of the world under an agreement with European company Ipsen.

Medicis' goal is to release one new product per year, Prygocki said.

"The aesthetic side of our business will continue to be enhanced through product line approvals, the expansion within the aesthetics market, the depth of our pipeline and our financial stability," Prygocki said.

Medicis is a Scottsdale, Ariz., specialty pharmaceutical company focused on the treatment of dermatological and podiatric conditions and aesthetics medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.